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In most epidemilogical studies, the problem of confounding adds to the uncertainty in conclusions drawn. This is also true for
studies on the eﬀect of maternal drug use on birth defect risks. This paper describes various types of such confounders and
discusses methods to identify and adjust for them. Such confounders can be found in maternal characteristics like age, parity,
smoking,useofalcohol,andbodymassindex,subfertility,andpreviouspregnanciesincludingpreviousbirthofamalformedchild,
socioeconomy, race/ethnicity, or country of birth. Confounding by concomitant maternal drug use may occur. A geographical or
seasonal confounding can exist. In rare instances, infant sex and multiple birth can appear as confounders. The most diﬃcult
problem to solve is often confounding by indication. The problem of confounding is less important for congenital malformations
than for many other pregnancy outcomes.
1.Introduction
The golden standard in medical clinical science is the
randomized double-blind study. There are, however, many
situations when this method is not applicable for ethical
reasons. One such situation refers to use of drugs during
pregnancy and pregnancy outcome. It would be unethical to
randomize sick or healthy pregnant women or women who
plan pregnancy to the use of a speciﬁc drug or a placebo.
Conclusions therefore have to be based on nonrandomized
epidemiological studies when exposure (use of drugs) occurs
spontaneously. Notably when moderate eﬀects occur, such
studies are open to criticism for many reasons, for example,
biasinexposureoroutcomedataanddiﬃcultyinthecontrol
of confounding.
If one is studying the relationship between maternal use
of a speciﬁc drug (e.g., an antidepressant) and the presence
of, for instance, congenital malformations in the oﬀspring
an observed relationship may not be due to eﬀects of the
drug.Ifafactordirectlyaﬀectsbothexposureandoutcome,a
confounding will exist and adjustment for it is needed. This
situation is schematically shown in Figure 1(a) and can be
exempliﬁedwithmaternalageasaconfounderintheanalysis
of maternal smoking and the risk for Down syndrome. In
a crude analysis, maternal smoking seems to decrease the
risk for Down syndrome with an odds ratio (OR) of 0.77.
If, however, one adjusts for the fact that pregnant women
smokelesswithincreasingageatdeliveryandthattheriskfor
Downsyndromeincreaseswithwoman’sage,theORchanges
to 0.94 and is far from being statistically signiﬁcant. The
opposite eﬀect is obtained if the exposure is a drug, the use
of which increases with maternal age, and Down syndrome
is the outcome. This will result in an increased crude OR.
If adjustment is made for maternal age, the eﬀect may
disappear. These two examples also show that confounding
can result in a too low risk estimate or a too high estimate,
depending on whether the eﬀects of the confounder are in
theoppositeorthesamedirectiononexposureandoutcome.
Various methods have been used in studies on the eﬀect
of maternal drug use on pregnancy outcome. These were
discussed by the author in an earlier article [1]. Many
diﬀerent pregnancy outcomes can be studied, for example,
miscarriage, congenital malformations, preterm birth, low
birth weight, intrauterine growth retardation, neonatal mor-
bidity, and long-term morbidity including eﬀects on neu-
ropsychiatric development and risk of cancer. The problem
of confounding will be relevant for all outcomes.2 Obstetrics and Gynecology International
2.MaterialandMethods
Most data discussed in the paper are based on published
material. Some new data are obtained by analyses of Swedish
Health Registers and notably of the Swedish Medical Birth
Register. Such analyses were made with Mantel-Haenszel
methodology with adjustment for relevant covariables.
Details of this register are available in [2].
3. Results andDiscussion
3.1. Methods for the Control of Confounding. Diﬀerent meth-
ods exist for the control of confounders. This can be done
by matching. If the study is a case-control study, controls to
cases are then selected with, for instance, the same maternal
age and other characteristics one wants to adjust for. If it is
a cohort study, the unexposed subjects are selected with the
same characteristics as the exposed subjects. Either matching
is made by selection of pairs or triplets (or more) of case and
control(s) with similar characteristics, or a group of controls
is chosen with a composition similar to the whole group of
cases (“frequency matching”).
More common, notably when large data sets are ana-
lyzed, is to adjust for the confounder(s) in the statistical
analysis. The most common way to do this is by using a
logistic regression model. This is a regression method to
predict outcome (e.g., rate of congenital malformations)
as inﬂuenced by one or more confounding factors. In the
standard analysis, such predictions are based on linear
regressions which may be inadequate, but it is obviously
possible to replace them with other mathematical functions
which more adequately describe the relationship between a
certain variable and the outcome. (The basic formula for a
logistic regression is: ln(p/(1 − p)) = α + β1 ∗ X1 + β2 ∗
X2 + ···+βn ∗Xn, where ln(p/(1 − p)) is the logarithm for
the odds of the occurrence of the outcome, α is a constant,
and the various β are regression coeﬃcients for X,w h e r e ,f o r
instance, β1 and X1 represent the exposure under study and
β2 to βn and X2 to Xn the various studied confounders. The
regression coeﬃcients can be transformed to odds ratios.)
When the relationship is U-formed, a linear regression may
not reveal the relationship properly but the ﬁtted straight
line may be nearly horizontal, indicating no relationship.
There are many advantages with this method, for instance,
that quantitative data do not have to be grouped and that
estimates can be made by interpolations when control data
are missing. It should be remembered that the eﬀect of
each one of the studied variables represents the eﬀect after
adjustment for the other included factors. If, for instance,
maternal age and parity are both added in the formula, the
odds ratio for maternal age will represent the eﬀect of age
adjusted for parity and vice versa.
Another method, especially useful when analyses are
based on very large materials, is the Mantel-Haenszel
technique.Inthistechnique,casesandcontrolsarecompared
within a number of strata, deﬁned by chosen confounders,
for example, maternal age group, parity group, and smoking
group. Within each stratum, the occurrence of exposure
among cases is compared with the occurrence of exposures
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Figure 1: Diagrams showing relationships between exposure,
outcome, and a third factor.
among controls and a summary chi-square is calculated
(based on one degree of freedom) which gives the average
association between exposure and outcome after adjustment
for the confounders. When this method is applied to
materials of limited size, controls may be missing in some
strata which are then rejected, reducing the power of the
study. When large control materials are present (like in
register studies) this risk is small.
The methods can of course also be used to characterize
the importance of the selected putative confounders for
exposure and for outcome separately and in the ﬁnal
analysis only true confounders (aﬀecting both exposure and
outcome) can be included.
In most instances, the two methods give rather similar
results.
Logistic regression is used in analyses aiming at risk
determinations in a dichotomous situation, for instance,
presence or absence of a malformation. When outcome can
show a number of quantitative eﬀects (e.g., IQ) a multiple
regression model will be used instead. The adequacy of the
statistical model is equally important in both methods.
The decision on the inclusion of confounders in the ﬁnal
analysis can be made in diﬀerent ways. It is obvious that
factors which in the analysis are identiﬁed as confounders
(i.e., aﬀect both exposure and outcome) should be included.
Sometimesotherfactors,knownfrompreviousstudiesorthe
literature as confounders, are included. It is rather common
that one includes also factors which only aﬀect exposure or
outcomebutnotboth. Suchfactorsarethusnot confounders
and should not be included but if they are, it does not matter
much.
3.2. Confounding and Stratiﬁcation: The Example of Infant
Sex. Confounding should be kept apart from the possibility
that the eﬀect of the exposure diﬀers, for instance, in male
and female fetuses, that infant sex modiﬁes the eﬀect of
exposure. If this is the case, the odds ratio obtained with or
without sex adjustment will be somewhere between that for
male and that for female infants. This can be seen from a
studyofmeclozineandsubluxationofthehip.Theoddsratio
for this condition after maternal use of meclozine in maleObstetrics and Gynecology International 3
infants is 1.16 (95% CI 0.92–1.45) and in the female infant
0.83 (95% CI 0.70–0.99). These two estimates diﬀer: z =
2.27, P = 0.03. This means that the drug (or the condition
which is the indication for drug use) reduces the risk for hip
subluxation in girls but not (or at least less) in boys. There
exist arguments that this condition has diﬀerent etiology in
the two sexes. This procedure is an example of stratiﬁcation
in the analysis in order to see if an eﬀect diﬀers in subgroups
ofthematerial,inthiscasebetweenboysandgirls.Whenone
makes such subgroup analyses it is important to remember
that the chances for random “signiﬁcances” increases with
thenumberofsubgroupsstudiedandifdiﬀerencesarefound
one must verify that they are not due to chance (which thus
seems not to be the case in example above). One way to
explore such a possibility is to add, in a logistic regression
analysis,aninteractiontermbetweenexposureandinfantsex
to see if the latter factor modiﬁes the eﬀect of the exposure. If
this interaction term is statistically signiﬁcant, it means that
both sex and exposure aﬀect the outcome risk and that the
eﬀect of exposure diﬀers according to infant sex.
An extreme situation is when outcome like hypospadias
is only present in one sex. Intuitively, one would then com-
pare exposures between infants with hypospadias and male
infants without hypospadias. If exposure is independent of
infant sex (which is true for most drugs), the result of only
comparingwithmalecontrolinfantsistoreducethematerial
which is used for estimating the background exposure rate
and therefore slightly widen the conﬁdence interval.
3.3. Adjusting for Intermediary Factors in the Pathway of the
Eﬀect of the Exposure on the Outcome. To adjust for a non-
confounder usually does not change the eﬀect of the
exposure—sometimes confounders are simply deﬁned as
factors which change the risk estimate with, for instance,
10% or more. There is another common situation, where
adjustment may give results which can easily be misunder-
stood. If the exposure acts via an intermediary phenomenon
whichaﬀectsoutcome,adjustmentforthephenomenonmay
remove the eﬀe c tm o r eo rl e s sc o m p l e t e l y( Figure 1(b)).
We can exemplify this phenomenon from studies of
neonatal conditions where the eﬀect is more easily seen than
in studies of birth defects. If maternal use of a drug increases
the risk for preterm birth, any neonatal condition which
occurs at an increased rate among preterm newborns will
probably be increased after the exposure. If this is the only
way in which the drug aﬀects the neonatal condition, the
eﬀectwilldisappearafteradjustmentforgestationalduration
or a paradoxical eﬀect can even be obtained. A classical
example is that maternal smoking increases perinatal mor-
tality but after adjustment for gestational duration or birth
weight, the increased risk changes to a seemingly protective
eﬀect [3]. One will then compare infants born of smoking
w o m e n( w h i c ha r eb o r np r e t e r mo rw i t hl o wb i r t hw e i g h t
because of the smoking but may be otherwise healthy) with
infants born of nonsmoking women. Some of the latter
infants are born preterm or with low birth weight because
of fetal pathology and are therefore at an increased risk for
perinatal death.
In such situations, the proper way of analysis is to look at
the eﬀect of exposure without considering the intermediary
factor. If one wants to see, if the eﬀect of the exposure is
solely or partly due to an intermediary factor, the eﬀect will
disappearifadjustmentismadeforit.Thismaybeofinterest,
for instance, if one wants to ﬁnd out if an eﬀect of a speciﬁc
drug occurs by a direct pharmacological action on the infant
or if it an eﬀect of an intermediary, for example, an increased
risk for preterm birth.
We can exemplify this with the eﬀect of late pregnancy
use of certain CNS active drugs on neonatal morbidity
(Table 1). Such neonatal morbidity is markedly more fre-
quent in preterm than in term infants and also occurs more
often in infants born by mothers using CNS-active drugs
duringlatepregnancythaninotherinfants.Ifthishadmerely
been an eﬀect of preterm birth, a risk among term birth
should not be seen but it is actually slightly higher than for
all births.
In studies of birth defects, which originate early in
the pregnancy, such intermediary eﬀe c t sa r em o r ed i ﬃ-
cult to detect. In this situation, another relationship may
appear.Infantswithsomecongenitalmalformationsareborn
preterm more often than expected and use of a drug may
increase the risk for preterm birth. Figure 1(c) illustrates
this situation. As a rule, preterm birth cannot cause the
malformation, so gestational duration is no intermediary
and no confounder and generally no adjustment should be
made for gestational duration. The drug could, however,
aﬀectforinstancetheplacenta,whichcouldbothincreasethe
risk for preterm birth and for the occurrence of a congenital
malformation. That such a mechanism can exist may be
suggested by the observation that malformed fetuses already
in mid-gestation may have an increased risk of being small
fordate,leadingtomisdatingfrom2ndtrimestersonography
[4]. The placenta eﬀect would then be an intermediary in
both causative pathways and the situation is the same as in
the situation of an intermediary as discussed in the former
paragraph.
3.4. Confounding by Maternal Characteristics
3.4.1. Maternal Age. This is a classical confounder in many
studies of teratogenic eﬀects of drugs. The eﬀect of maternal
age (5-year classes) on the risk for any relatively severe
congenital malformation is seen in Table 2. Note that each
studiedvariableinthisTableisadjustedforallothervariables
in the table in order to identify speciﬁc eﬀects of each
variable. There is a not very strong J-shaped relationship
between maternal age and the risk for any relatively severe
malformation. Malformations vary with respect to maternal
age dependency, however. In a few, a strong increase in
infants born of young women is seen. The most well-known
example is gastroschisis, for which the odds ratio at age
<20 in the present material is 4.51 (95% CI 2.63–7.71) and
at age 20–24 it is 2.41 (95% CI 1.67–3.48), using age 25–
29 as a reference. For many other malformations, the risk
increases with maternal age, and for some, like trisomies,
the risk increases sharply at high age. For Down syndrome,4 Obstetrics and Gynecology International
Table 1: Risk of neonatal morbidity a according to preterm birth and maternal use of CNS-active drugs b after the ﬁrst trimester (both 2nd
and 3rd trimester). Among all infants, 6.0% were born preterm, and among infants of women using CNS-active drugs, 8.2% were born
preterm.
Infant group With neonatal pathology Total number % OR 95% CI
All infants 22015 315975 7.0 1.00 Reference
Preterm births 7465 18836 39.6 12.3 12.0–12.7
CNS-active drugs, all infants 541 4425 12.2 1.83 1.67–2.00
CNS-active drugs, term infants 380 4009 9.5 2.05 1.84–2.28
aInfantmorbidityconsistsofoneormoreofthefollowingconditions:respiratorydisorders(ICD-10codesP22–P28),hypoglycaemia(P70.4–P70.9),neonatal
convulsions (P90), other disturbances of cerebral status (P91), low Apgar score (Apgar 5 minutes <7).
bThe drugs studies include opioids, anticonvulsants, antipsychotics, sedative/hypnotics, and antidepressants.
Table 2: Impact of various maternal variables on the risk for any relatively severe congenital malformation in the infants and on the use of
antidepressant drugs.
Relatively severe malformation a Maternal use of antidepressants
Variable OR 95% CI OR 95% CI
Maternal age
<20 1.07 0.99–1.15 0.69 0.60–0.79
20–24 1.04 1.00–1.07 0.91 0.86–0.97
25–29 1.00 Reference 1.00 Reference
30–34 1.00 0.97–1.02 1.19 1.14–1.24
35–39 1.02 0.99–1.06 1.52 1.99–1.60
40–44 1.15 1.08–1.23 1.78 1.62–1.96
≥45 1.02 0.74–1.41 2.36 1.60–3.49
Parity
1 1.00 Reference 1.00 Reference
2 0.89 0.87–0.91 0.67 0.64–0.70
3 0.90 0.87–0.93 0.85 0.80–0.89
≥4 0.89 0.85–0.93 0.84 0.78–0.90
Smoking
None 1.00 Reference 1.00 Reference
<10 cigs/day 1.06 1.03–1.11 2.39 2.27–2.51
≥10 cigs/day 1.09 1.03–1.15 3.84 3.63–4.07
Body mass index
<19.8 1.00 0.96–1.04 1.03 0.96–1.20
19.8–25.9 1.00 Reference 1.00 Reference
26–29.9 1.09 1.06–1.11 1.22 1.17–1.27
30–39.9 1.15 1.11–1.20 1.49 1.41–1.57
≥40 1.39 1.23–1.56 2.19 1.92–2.50
Number of years of unwanted childlessness
0 1.00 Reference 1.00 Reference
1 1.02 0.95–1.09 0.89 0.88–0.99
2 1.08 1.01–1.15 0.90 0.81–1.01
3 1.12 1.02–1.29 0.66 0.56–0.78
4 1.30 1.17–1.45 0.80 0.65–0.98
≥5 1.30 1.25–1.41 0.82 0.71–0.95
Number of previous miscarriages
0 1.00 Reference 1.00 Reference
1 1.05 1.02–1.05 0.99 0.95–1.04
2 1.05 0.98–1.11 1.08 0.99–1.17
≥3 1.12 1.02–1.32 1.15 1.01–1.30
aAny congenital malformation with the exception of the following conditions which are common and variably registered: preauricular tag, patent ductus at
preterm birth, undescended testicle, hip (sub)luxation, tongue tie, single umbilical artery, nevus.Obstetrics and Gynecology International 5
for instance, the risk increases at 30–34 years to 1.76 (95%
CI 1.52–2.03) and at 40–44 years age to 6.66 (95% CI 1.94–
24.4). The eﬀect of maternal age will therefore depend on the
speciﬁc malformation under study.
Often the maternal age eﬀect on the use of drugs is
strong. In Table 2, data for the use of antidepressant drugs
in early pregnancy is shown as an example. The maternal
age eﬀect on drug use varies markedly with the drug
type [2]. Use of antiasthmatic drugs is, for example, more
prevalent among women delivering at a young age (<25
years) than among older women while antihypertensives
show the opposite distribution.
If adequate adjustment for maternal age is not made, the
estimated risk after maternal use of a drug may be falsely
exaggerated or underestimated according to the directions of
the age eﬀect on malformation risk and on the use of the
drug. For the outcome of any congenital malformation the
eﬀect is usually weak but for speciﬁc malformations it can be
of greater importance.
3.4.2. Maternal Parity. The deﬁnition of the parity concept
diﬀers. In this text, parity 1 means that the woman had
her ﬁrst child and, for instance, parity 3 that she had two
previouschildren (whichcouldhave been twins).Sometimes
parity0ornulliparityisusedforwomenattheirﬁrstdelivery.
Theriskforanyrelativelyseverecongenitalmalformation
(Table 2) is slightly higher at parity 1 than at higher parities
but there is no change of risk between parities 2 and higher
parities. For most speciﬁc malformations, the parity eﬀect is
small. For esophageal and anal atresia, an increased risk at
parity 1 is seen [5] but for cleft lip/palate, an increased risk at
high parity seems to exist [6].
3.4.3. Maternal Smoking and Use of Alcohol or Illegal Drugs in
Early Pregnancy. The eﬀect of maternal smoking on the risk
forinfantmalformationhasbeenmuchdiscussed.According
to Table 2, there is a weak eﬀect on any relatively severe
congenital malformation with an odds ratio of less than 1.1.
The eﬀect of smoking varies according to malformation type
studied [7] but is much stronger for intrauterine growth
and birth weight [8]. For cleft lip/palate the increased risk
after maternal smoking is rather well established while data
for many other conditions are scarce. As seen in Table 2,
smoking is much more prevalent among women who use
antidepressants and the same is true for the use of many
other CNS active drugs. The speciﬁc relationship with
diﬀerent drug groups can be found in [2]. One interesting
such relation is with antihistamines where smoking is less
prevalent than expected, notably for antihistamines used
for nausea and vomiting in pregnancy (NVP). There are
argumentssuggestingthattherelationisnotexplainedbythe
fact that women with NVP stop smoking but that NVP is less
prevalent among smoking women who get pregnant [9].
Adjustment for maternal smoking is thus at least some-
times needed. Such adjustment can be made using a yes/no
question but a quantitative estimate is often preferable,
notablywhenthesmokingeﬀectisstrong.Howdetailedsuch
a quantiﬁcation should be made depends on the available
possibilities.Oftenadivisionintosmoking<10cigarettesper
day and 10 or more cigarettes per day is made as in Table 2.
There is no convincing diﬀerence between the groups in the
columnforrelativelyseveremalformationsbutdeﬁnitelyone
in the column for antidepressant use.
Alsotheuseofothernicotinepreparationsmayoccur,for
example, snuﬃng and nicotine applications for treatment of
smoking addiction. Some evidence has been presented for a
teratogenic eﬀect also at these administrations but no ﬁrm
conclusions can yet be drawn and more data are needed.
Hypoxiaorcarbonmonoxideandnotnicotinemaycausethe
teratogenic action of maternal smoking [10].
In a few instances, maternal smoking appears to have a
“protective” eﬀect with a lower malformation risk among
infants of smokers than of nonsmokers, for example, neural
tube defects and hypospadias [7]. The mechanism behind
this is unclear.
Complex addiction is common, and there is a strong
association between smoking and alcohol use. The eﬀect
of the use of large amounts of alcohol on the embryo is
well known and can result in a recognizable “fetal alcohol
syndrome” [11] in which presence of a cardiac defect is one
component. A teratogenic eﬀect of moderate amounts of
alcohol is more dubious [12]. Associations between alcohol
use and some speciﬁc malformations like omphalocele and
gastroschisis have been based on retrospective studies with
ar i s kf o rr e c a l lb i a s[ 13]. Information on alcohol use in
large numbers of individuals is diﬃcult to get from routine
questionnaires or interviews, and eﬀorts to adjust for con-
foundingfromalcoholusearethereforeoftenineﬀective.The
importance of alcohol as a confounder obviously depends
on the prevalence of alcohol use and abuse among pregnant
womenwhichprobablyvariesmuchbetweendiﬀerentpopu-
lations.Becauseofastrongassociationbetweensmokingand
alcohol use, adjustment for smoking (which is usually easier
to get reliable data on) may take care of at least part of the
confounding obtained by alcohol use.
It is also diﬃcult to get information on the use of illegal
drugs, notably in populations where such use is regarded as
unacceptable social behaviour. Use of many of these drugs
can have important eﬀects on pregnancy and infant mor-
bidity but usually they are not very important confounders
in studies of congenital malformations. It is true that some
of these drugs have been associated with speciﬁc teratogenic
eﬀects but these studies have been based on retrospective
exposure data collection with a risk for recall bias [14].
3.4.4. Body Mass Index. Increasing interest is being paid
to the possible impact of the ongoing obesity epidemic in
many parts of the world. Many ill eﬀects of prepregnancy
obesity on pregnancy outcome has been found, including an
increased risk for many (but not all) congenital malforma-
tions [15]. As is seen in Table 2, there is a clear-cut increased
risk in the risk for any relatively severe malformation and
obesity is also associated with a strongly increased use of
antidepressantdrugs.Leanness,ontheotherhand,ingeneral
seems not to aﬀect malformation risk.
The mechanism behind the eﬀect of obesity on malfor-
mation risk is unclear. A possible explanation is that obesity6 Obstetrics and Gynecology International
is associated with an increased risk for diabetes type 2 which
often goes unnoticed and undiagnosed for a long time and
which seems to have a teratogenic action similar to but
weaker than that of diabetes type 1 [16].
Information on the two variables which deﬁne body
mass index, weight and height, should refer to the time
just before pregnancy or possibly to early pregnancy while
weight at delivery is aﬀected by weight changes during
pregnancy which are of little interest for teratogenesis. The
information can be based on anamnestic information given
by the pregnant woman (with some uncertainty) or actual
measurements at the ﬁrst antenatal visit if this occurs early
in pregnancy. As long as the information is collected before
the outcome of pregnancy is known, it will be unbiased.
3.4.5. Subfertility. The usual measure of subfertility is how
many years the couple has tried to get a pregnancy before
they succeeded. Clinically, a waiting time of less than one
year is not regarded as indicating subfertility and the concept
of subfertility should not be mixed with the concept “time to
pregnancy,”whichusuallyindicatesthenumberofmenstrual
cycles which has passed before conception. It is known that
a period of unwanted childlessness increases the risk for
adverse pregnancy outcomes [17] including a moderately
increased risk for infant congenital malformations (Table 2).
This factor is of course especially important in studies
of drugs or other treatment for infertility, including in
vitro fertilization [18], but also the use of other drugs
may be aﬀected by subfertility. In Table 2 it is seen that
antidepressant use is reduced at long-standing subfertility
(3 years or more), a situation where various treatments
including in vitro fertilization may be considered. The
same phenomenon is seen for sedatives and hypnotics
[2]. Under these circumstances, the women may actively
try to increase the chance for conception and a healthy
pregnancy by avoiding use of these drug. Use of, for instance,
antihypertensives or antiasthmatics, on the other hand, is
associated with an increased occurrence of subfertility [2].
This may be due to a direct eﬀect of the underlying disease or
the drug on the possibility to conceive.
3.4.6. Previous Miscarriages. Ap r e v i o u sm i s c a r r i a g em a y
increasetheriskforacongenitalmalformationinanewborn,
and this risk may increase slightly if more than two previous
miscarriages have occurred (Table 2). For some conditions,
the relationship can be stronger than that. This can—like
threatenedabortionduringanongoingpregnancy—actasan
important confounder in analyses of drugs which are used
to treat these conditions. Some confounding eﬀect can also
be obtained for other drugs. In Table 2, for instance, it can
be seen that repeated previous miscarriages (3 or more) are
associated with an increased use of antidepressants and a
similar relation exists for sedatives and hypnotics [2].
3.4.7. Previous Birth of a Malformed Infant. For many mal-
formations, a genetic component is important, for example,
orofacial clefts, neural tube defects, and cardiac defects. The
presence of an older sibling or other close relative with
such a malformation will therefore aﬀect the risk for a
malformation in a new pregnancy. This phenomenon will be
ac o n f o u n d e ri na n a l y s e so fd r u ge ﬀects only if the birth of
an infant with a malformation will aﬀect the use of drugs in
the following pregnancy. There is little information on this
available. An ongoing study using the Medical Birth Register
in Sweden indicates the complexity of this issue. The odds
ratio for using (and reporting) a drug in early pregnancy
is actually higher in women who had a malformed infant
in a previous pregnancy compared to other women after
adjustment for year of birth, maternal age, parity, smoking
in early pregnancy, and BMI. The OR is only 1.14 (95% CI
1.08–1.21), and its size depends on the type of malformation
that occurred: it is increased for neural tube defects and for
cardiovascular defects but not for orofacial clefts, alimentary
tract atresia, severe kidney malformations, hypospadias, or
chromosome anomalies. The increased OR for neural tube
defects is nearly exclusively explained by the use of folic acid.
For cardiac defects, the main contribution is not only from
insulin but also from psychopharmaca.
For any relatively severe malformation, the OR varies
with the drug category (Table 3). The highest OR has folic
acid, insulin, psychopharmaca, thyroid drugs, and NSAID
(nonsteroid anti-inﬂammatory drugs). Also for anticon-
vulsants and antihypertensives ORs are high although not
statistically signiﬁcant.
That folic acid is used more often in the pregnancy
following a birth of a malformed infant (notably neural tube
defect) is reasonably the result of a therapeutic tradition,
notably the recommendation of high doses of folic acid
after a pregnancy complicated with a neural tube defect. A
protective eﬀect of folic acid for cardiovascular defects has
also been suggested even though evidence is less clear in that
case. In the (rather few) instances when folic acid use is due
toapreviousmalformationwithasigniﬁcantrecurrencerisk,
a confounding will exist.
For some other drugs the explanation of an increased OR
may be the following. If the woman has a chronic disease
like diabetes type 1 which has a marked teratogenic eﬀect,
the presence of such a defect (e.g., a cardiovascular defect)
in a previous pregnancy can be due to the disease. As this
is a chronic condition, any following pregnancy in such
women will be characterized by maternal diabetes type 1
and use of insulin. Possibly a similar relationship is seen
for hypothyreosis, epilepsy, and chronic hypertonia; all these
diseases and drugs used for treating them are associated with
a moderately increased risk for infant cardiovascular defects.
A previous child with a malformation caused by the disease
will then not act as a confounder.
A third possible explanation is especially applicable to
psychoactive drugs. If the burden of a handicapped or sick
child increases the use of this type of drugs, women with
a previous birth of a malformed infant will be more likely
to use such drugs, and in this situation, the presence of a
previous child with a malformation will represent a true
confounder.
There is little evidence that the birth of a previous mal-
formed child will reduce drug use in a following pregnancy.
Innone oftheanalysesperformed,anORsigniﬁcantlyunder
1.0 was found.Obstetrics and Gynecology International 7
Table 3: Use of drugs in early pregnancy among women with a previous relatively severely malformed infant compared with women who
had no known previous such malformed infant. Odds ratio (OR) with 95% conﬁdence interval (95% CI) adjusted for year of delivery,
maternal age, parity, smoking in early pregnancy, and BMI.
Drug group Among women with
previous malformed infant
Among all women OR 95% CI
Any drug 2078 290480 1.14 1.08–1.21
Drugs for stomach ulcer and reﬂux 53 6062 1.17 0.89–1.55
Insulin 43 2614 2.46 2.81–3.32
Multivitamins 218 56200 0.99 0.86–1.15
Folic acid 276 43780 1.26 1.12–1.43
Antihypertensives 35 3147 1.39 0.99–1.94
Thyroid drugs 104 10728 1.31 1.07–1.59
Antibiotics 186 19036 1.04 0.89–1.20
NSAID 127 13047 1.27 1.06–1.52
Opioids 38 3974 1.18 0.85–1.63
Minor analgesics 449 51043 0.96 0.87–1.06
Anticonvulsants 20 2037 1.44 0.92–2.26
Antipsychotics 26 1992 1.53 1.03–2.39
Sedatives/hypnotics 32 3301 1.21 0.91–1.83
Antidepressants 95 11714 1.26 1.02–1.55
Any psychopharmacon 137 15558 1.29 1.08–1.53
Drugs for rhinitis 67 9944 0.86 0.68–1.10
Antiasthmatic drugs 180 22702 1.07 0.92–1.25
Antihistamines 300 38689 0.98 0.87–1.10
Ad i ﬀerent question is if a drug eﬀect diﬀers between
cases with and without a known genetic risk for a malfor-
mation. By identifying women who already had a pregnancy
with the same malformation as in the current pregnancy
product, a crude division can be made between genetic high-
risk and low-risk fetuses. To explore the impact of genetics
on the drug eﬀect a stratiﬁcation of the material can be made
into women with and without previous pregnancies with the
malformation in question [19]. Unfortunately, numbers are
usually so low in the former group that the study does not
become informative. One could believe that by excluding
infants with a genetic load from the study, the sensitivity for
the drug teratogeneic eﬀect should increase. On the other
hand, the drug may act only on a genetic background by
increasing the penetrance of the genes which contribute to
the origin of the malformation.
Similarly, studies have been made where cases were
divided into presence or absence of speciﬁc genes, associated
with the origin of a certain malformation—again numbers
have usually been so low that no ﬁrm information was
obtained [20].
3.4.8. Prenatal Diagnosis and Induced Abortion. Some con-
genital malformations can be identiﬁed by various methods
applied during pregnancy, and if the malformation is
regarded as serious this may result in an interruption of the
pregnancy. This is a problem in data collection but could
also lead to confounding. Use of a drug—or more likely
the underlying disease—may aﬀect the probability that a
prenatal fetal investigation is carried out or could aﬀect its
degree of detail. This has, for instance, been suggested to
occur in depressed women. This problem is most important
in populations where all pregnant women do not routinely
getasonographicexaminationwhich,forinstance,isthecase
in the Scandinavian countries.
3.4.9. Socioeconomy. T h ei m p o r t a n c eo fp a r e n t a ls o c i o e c o n -
omy varies according to the pregnancy outcome investigated
and the population studied. To a large extent, socioeconomic
eﬀects can be explained by lifestyle factors, for example,
smoking and obesity, the eﬀects of which can be directly
controlled when such data are available. For some outcomes,
some eﬀects of socioeconomy will remain but it is doubtful
to what extent this is true for birth defects. One possible
pathway would be via nutrition and food quality. Such
eﬀects are probably much stronger in societies with large
socioeconomic diﬀerences than in wellfare societies. This
may be an explanation that socioeconomy appears to be
related to neural tube defects in some countries like Great
Britain [21] and USA and is hardly discernible in North
European countries like Sweden.
Also the impact of socioeconomy on drug usage depends
on the wellfare situation in the society. When medical care
is free or associated with low costs, the impact will probably
be less than in societies where the patients to a large extent
have to pay for medical care and drugs. Obviously, there
are also socioeconomic diﬀerences in disease rates which
aﬀectdruguse.Table 4 showsthediﬀerenteﬀectsofmaternal
education level for some drug groups. Even though many
show statistically signiﬁcant deviations, the ORs are only8 Obstetrics and Gynecology International
Table 4: Importance of maternal education level in Sweden for the use and/or reporting of various categories of drugs in early pregnancy
[2]. Nine years of education is compulsory. Most women have 12 years of education which is used as the reference group. Adjusted for year
of delivery, maternal age, parity, smoking, and BMI.
Low education, <12 years of education High education, ≥14 years of education
Drug group OR 95% CI OR 95% CI
Drugs for ulcer and gastrointestinal reﬂux 1.20 1.08–1.53 0.81 0.75–0.88
Multivitamins and minerals 0.92 0.66–1.29 1.11 0.89–1.38
Anticoagulants 1.04 0.81–1.33 0.96 0.81–1.14
Haemostatics 1.42 1.01–2.00 1.08 0.85–1.38
Antihypertensives 0.85 0.71–1.00 0.82 0.73–0.92
Oral contraceptives in early pregnancy 0.88 0.87–1.02 0.72 0.62–0.83
Systemic corticosteroids 0.86 0.72–1.01 1.03 0.92–1.15
Thyroxine substitution 0.91 0.82–1.01 0.91 0.84–0.97
Antibiotics 0.90 0.85–0.95 1.07 1.03–1.11
Antivirus drugs 0.84 0.85–1.37 1.35 1.08–1.69
Vaccines 0.92 0.62–1.35 1.53 1.26–1.86
NSAID 0.90 0.83–0.97 0.87 0.82–0.92
Analgesics 1.04 1.01–1.08 0.93 0.91–0.96
Drugs for migraine 0.92 0.76–1.11 0.85 0.75–0.97
Anticonvulsants 1.49 1.26–1.76 0.71 0.61–0.82
Antipsychotics 1.52 1.17–1.99 0.97 0.93–1.28
Sedatives/hypnotics 1.75 1.56–1.96 0.86 0.76–0.98
Antidepressants 1.48 1.35–1.61 0.78 0.72–0.85
Drugs used for malaria prophylaxis 0.87 0.55–1.37 2.08 1.08–2.57
Antiasthmatics 0.96 0.91–1.02 0.90 0.97–0.99
Antihistamines used for allergy 0.77 0.70–0.82 1.11 1.05–1.17
Ophthalmics 0.63 0.47–0.86 1.35 1.17–1.56
Table 5:Importanceof maternal education ornon-cohabitation foroccurrence and diagnosis ofcongenital malformationsinSweden. Odds
ratios(ORs)with95%conﬁdenceintervals(95%CI)forvariousmalformationgroupsatdiﬀerentmaternaleducationlevels.Foreducational
level, the reference is 12 years of education, for non-cohabitation, the reference is cohabitation. Adjustment for year of birth, maternal age,
parity, smoking, and BMI.
<12 years of education ≥14 years of education Non-cohabiting in early pregnancy
Malformation group OR 95% CI OR 95% CI OR 95% CI
Relatively severe malformations 1.05 1.00–1.10 0.97 0.93–1.00 0.99 0.95–1.06
Chromosome anomalies 1.04 0.86–1.26 0.96 0.84–1.10 0.99 0.75–1.29
Neural tube defects 0.75 0.40–1.16 0.97 0.73–1.30 1.49 0.89–2.48
Orofacial clefts 0.99 0.81–1.21 0.89 0.77–1.03 0.95 0.71–1.26
Cardiovascular defects 1.02 0.94–1.61 0.97 0.87–1.08 1.08 0.97–1.22
Severe kidney malformation 1.07 0.78–1.46 0.98 0.86–1.13 0.99 0.62–1.57
Hypospadias 1.24 1.06–1.45 0.78 0.62–0.98 0.85 0.66–1.10
Pes equinovarus 0.86 0.69–1.07 0.94 0.69–1.26 1.00 0.75–1.33
(Sub)luxation of hip 0.90 0.80–1.01 0.98 0.64–1.49 0.76 0.63–0.91
Craniostenosis 0.75 0.53–1.07 1.01 0.68–1.51 0.94 0.58–1.54
slightly increased or decreased, but for some drug groups
and notably for CNS active drugs, more marked diﬀerences
are seen. To what extent these diﬀerences are due to diﬀerent
prevalence of underlying disease or to diﬀerent drug use at
similar underlying disease patterns is diﬃcult to disentangle.
Thesigniﬁcanceofsocioeconomicfactorsasconfounders
varies between populations, mainly according to the impact
on malformation risk. Table 5 indicates that, in Sweden,
maternal education as a proxy for socioeconomic level has
little impact on malformation rate if adjustment is made for
age, parity, smoking, and BMI. For speciﬁc malformations
and notably for hypospadias, an association seems to exist
with a moderately increased risk at short education and a
possibly lower risk at high education. This could confoundObstetrics and Gynecology International 9
an analysis, for instance, of the possible eﬀect of hormonal
treatment on hypospadias risk. For severe kidney malforma-
tions, a reduced risk is seen for infants of women with a high
education. It can be noted that no eﬀect of socioeconomic
level is seen on the risk for an infant with a chromosome
anomaly which indicates no diﬀerence in prenatal detection
rate according to maternal education, and there is no eﬀect
on (sub)luxation of the hip, a condition sensitive to variable
diagnostic and reporting completeness. The classical eﬀectof
socioeconomy on neural tube defect risk is not seen in this
material.
Maternaleducationisonewaytoevaluatesocioeconomic
conditions. In some societies, the man’s education plays a
more important role than the female’s for the socioeconomy
ofthefamily.Formalsocialgroupclassiﬁcationsexistinsome
countries. Family income may be a useful variable when
known, but in many wellfare societies with extensive social
security systems and usually also high tax rates, this measure
may be less sensitive.
A further variable which can be used is if the woman is
cohabiting or not with the man at the beginning of preg-
nancy. In Sweden only 3.3% of the women who give birth
arenot cohabitingin earlypregnancy—this maybe theresult
of the abortion law which permits abortions without any
restrictions before week 12. Table 5 demonstrates the weak
eﬀect of this variable on malformation risk—a “protective”
eﬀect is seen on (sub)luxation of hip which may be a result
of multiple testing.
When other outcomes than congenital malformations
are studied, like preterm birth and intrauterine growth
retardation, socioeconomic level can have a stronger eﬀect.
3.4.10.Race/EthnicityandCountryofBirth. Inmanypopula-
tions, race or ethnicity is an important confounder in
reproduction epidemiology. Other populations are rather
homogeneous from a racial point of view. In some societies
information on race is not politically possible to record (e.g.,
in Sweden). In such areas, sometimes country of birth can
give an idea of these factors but noticed eﬀects can also
be related to the status of being an immigrant. Analyses
of the eﬀect of maternal country of birth on pregnancy
outcome in Sweden indicated that only few groups may
deviate from Swedish-born women, among them women
from Sub-Saharan Africa [22]. They will make up a rather
small proportion of the studied population.
Table 6 shows that the country of birth of the woman
sometimes slightly aﬀects the risk for an infant with a
relatively severe malformation. Due to the large numbers
involved, some odds ratios reach statistical signiﬁcance even
though the magnitude of the deviation is small. Both women
born in the other Nordic countries and women born in
non-Nordic countries have a slightly decreased risk for a
malformation in the infant. These women have moved to
Sweden for various reasons. One group (often from Asia)
were adopted as children and have lived most of their life in
theSwedishsocietyandhaveSwedishastheirnativelanguage
but carry the genetic load of their country of origin. Some
women were born by Swedish parents who at that time were
living abroad. Other women have immigrated as refugees
from catastrophe or war areas; some have immigrated
for purpose of searching work (often highly educated) or
because they had a relationship with a Swedish man.
The weak tendency to a malformation risk slightly below
that for Swedish-born women could perhaps be explained by
a“healthyimmigrant”eﬀect,thatatleastsomeofthereasons
listed above will favour women without chronic diseases.
The genetic composition will vary between geographical
areas why speciﬁc conditions may be present for speciﬁc
malformations. As an example diﬀerent rates of neural tube
defects in USA are seen when white, black, and Hispanic
populations are compared [23].
The pattern of drug use during pregnancy often diﬀers
according to country of birth [2]. As a confounder, country
of birth will be rather weak but when in doubt it may be wise
to repeat an analysis based only on nonimmigrant women.
3.4.11. Confounding by Concomitant Use of Other Drugs.
Women often use combinations of drugs, and in studies of
onespeciﬁcdrug,otherdrugsmayactasconfounders,ifthey
are used more often together with than without the drug
under study and if they in themselves increase the risk for
instance of a birth defect. In Table 7 some examples are given
based on maternal use of antidepressants [24]. Many drug
groups are used in excess by these women. The strongest
relationship is seen with oral contraceptives and psychoac-
tive drugs: opioids, antipsychotics, and sedatives/hypnotics.
Weakerbutstatisticallysigniﬁcantrelationshipsareseenwith
drugs for stomach ulcer and reﬂux, systemic corticosteroids,
thyroid drugs, NSAIDs, antiasthmatic drugs, and antihis-
tamines. Much of these associations can be explained by
known comorbidity. On the other hand no associations is
seen with some drug groups, and some are used less often
by women taking antidepressants than by other women:
multivitamins, folic acid, and minor analgesics. It can be
debated if this mirror an actually lower use or is an eﬀect
of the fact that women may concentrate on reporting the
use of potentially harmful drugs and neglect common and
apparently harmless drugs.
Coexposure for diﬀerent drug categories can have dif-
ferent results. In order to act as confounders, the codrug
must in itself aﬀect outcome. This may be true for some
of the drugs listed but probably not for other, for example,
drugs for stomach ulcer or reﬂux and antihistamines. The
use of a nonteratogenic drug will not appear as a confounder
in studies of birth defects: even if it is associated with
the exposure under study as it does not associate with the
outcome under study. The number of women who have
been exposed to a putative teratogenic drug by coexposure
is usually low, and the exclusion of such cases in the analysis
may be the easiest way to deal with the problem.
There is another complication which can occur due to
exposure for two drug categories. Neither of the two drug
groups may have a noticeable teratogenic activity but when
usedtogethertheymay—theywouldactsynergistically.This,
for instance, was suggested in a study [25] indicating that
neither SSRI drugs nor benzodiazepines had an observable10 Obstetrics and Gynecology International
Table 6:Importanceofthemother’scountryofbirthontheoccurrenceofrelativelyseveremalformationsintheinfant.Oddsratiosadjusted
for year of birth, maternal age, parity, smoking, and BMI. Reference is infants born by mothers born in Sweden. Data for years 2000–2008.
Geographic area Number of infants % of all infants % malformed infants OR 95% CI
Sweden 727166 81.9 2.7 1.00 Reference
Other Nordic countries 16612 1.9 2.5 0.87 0.79–0.96
Western Europe,
Northern America,
Australia,
New Zealand
10504 1.2 2.6 0.96 0.85–1.08
Eastern Europe and former
Soviet Union
25855 2.9 2.5 0.89 0.83–0.97
Sub-Saharan Africa 15488 1.7 2.7 0.97 0.88–1.08
North Africa and Middle East 54186 6.1 2.9 1.04 0.98–1.09
Asia 27405 3.1 2.2 0.82 0.75–0.89
South and Middle America 10373 1.2 2.4 0.84 0.74–0.96
All non-Nordic countries 143811 16.2 2.6 0.94 0.91–0.98
Table 7: Concomitant drug use in early pregnancy among 11,181 women who used antidepressants [2]. Odds ratios (ORs) with 95%
conﬁdence intervals (95% CI) for use of speciﬁc group categories in women using antidepressants compared with women who did not.
Adjustment for year of birth, maternal age, parity, smoking in early pregnancy, and BMI.
Drug group Number of users OR 95% CI
Drugs for stomach ulcer and reﬂux 316 2.92 2.61–3.26
Drugs for inﬂammatory bowel disease 41 1.27 0.93–1.73
Insulin 49 1.13 0.85–1.50
Multivitamins 559 0.78 0.72–0.85
Folic acid 519 0.82 0.75–0.90
Oral contraceptives during pregnancy 160 3.52 3.02–4.11
Gonadotropins 22 0.85 0.56–1.28
Systemic corticosteroids 65 1.55 1.21–1.98
Thyroid drugs 317 1.89 1.69–2.11
Antibiotics 321 0.92 0.82–1.03
NSAIDs 300 1.21 1.08–1.36
Opioids 261 3.48 3.09–3.93
Minor analgesics 835 0.83 0.77–0.89
Anticonvulsants 110 3.17 2.63–3.82
Antipsychotics 283 7.13 6.39–7.97
Sedatives, hypnotics 1202 25.9 24.6–27.3
Drugs for rhinitis 146 0.92 0.78–1.09
Antiasthmatics 533 1.40 1.28–1.53
Antihistamines 1097 1.79 1.68–1.90
teratogenic eﬀect, but the combination of the two drugs had.
This observation, based on rather few cases, has not yet been
conﬁrmed in an independent material.
3.5. Confounding by Infant Characteristics
3.5.1. Infant Sex. Some malformations show a deviating sex
ratio,sometimesextreme(likehypospadiaswhichinpractice
only exists in males). Is there then a reason to adjust for
infant sex in the analysis of drug eﬀects?
If the use of a drug is aﬀected by infant sex, this would
lead to confounding and adjustment for sex should be made.
Thus, for instance, subluxation of the hip is more common
in girls than in boys (sex ratio 0.37 instead of 1.06 among
all neonates) and women who carry a girl fetus are slightly
more likely to experience nausea and vomiting in pregnancy
(NVP) and therefore also to use drugs for that condition (for
instance,antihistamineswithanantiemeticeﬀect).Inastudy
of the use of meclozine, the infant sex ratio was 0.92 instead
of 1.06 [26]. If one wants to study the possible relationship
between the use of meclozine (or NVP) and occurrence of
subluxation of the hip in the newborn, an adjustment for
infant sex is therefore called for. Actually, this changes the
odds ratio very little: from 0.95 (95% CI 0.82–1.08) to 0.91
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In most situations, infant sex is unrelated to drug
exposure and is therefore not confounder, even if the sex
distribution among the outcome is skewed. No adjustment
for infant sex is then called for. As pointed out above, infant
sex may modify the eﬀect of the drug which can be analyzed
by subgroup analysis according to sex.
3.5.2. Multiple Birth. The occurrence of multiple birth may
be aﬀected by drug treatments even though this situation
is rare. One such example is ovulation stimulation with,
for instance, clomiphene, leading to an increased rate of
twin pregnancies. In most instances, drug treatment in
early pregnancy does not aﬀect the rate of multiple births.
An example of a possible eﬀect is exposure to SSRI (but
not tricyclic antidepressants) when the twinning rate is
signiﬁcantly low [2] Some evidence exists that use of folic
acid may increase the twinning rate. Most of the changes in
twinning rate refer to dizygotic twins.
The malformation rate in twin infants diﬀers only little
fromthatinsingletonsandanincreasedriskismainlyseenin
monozygotictwins.Amongdizygotictwins,someconditions
associated with prematurity and perhaps with intrauterine
crowding may be increased.
In a situation when adjustment for twinning is needed,
it should be remembered that the eﬀect of drug use on
twinning rate concerns dizygotic twins, and if adjustment
is made for any twinning, one will underestimate the risk
for malformation after the exposure because in the reference
population the percentage of monozygotic pairs will be
higher than in the exposed population. This was clear in
studies of twins born after in vitro fertilization (IVF)—when
IVF twins were compared with spontaneously conceived
twins, the former appeared to show less neonatal pathology
than the latter, but when comparisons were made between
unlike sexed (dizygotic) pairs the IVF twins had a worse
outcome than the non-IVF twins [27].
3.5.3. Gestational Duration, Birth Weight, and Intrauterine
Growth. Infants with birth defects are sometimes born
preterm with low birth weight and signs of intrauterine
growth restriction. These expressions are the result of
the malformations or have a common cause with the
malformations, for example, placental insuﬃciency. They
are thus neither intermediaries, nor confounders, and there
is generally no reason to adjust for them. Only when a
birth defect is studied which is the result of preterm birth,
gestational duration can appear as an intermediary. This
could, for instance, be the case with undescended testicle and
persistent ductus arteriosus, both strongly associated with
preterm birth and hardly true malformations.
Birth weight strongly depends on gestational duration.
If the use of a drug increases the risk of short gestational
duration, it will usually also aﬀect birth weight as an
intermediarybetweenexposureandoutcomeandgestational
duration should not be adjusted for when one is interested in
the eﬀect on birth weight. If one makes such adjustments, a
remaining eﬀect on birth weight will indicate that the weight
of the infant at each gestational week deviates from the
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Figure 2:Percentageofinfantswithrelativelyseveremalformations
and percentage of women who used antiasthmatics in early
pregnancy in 21 counties in Sweden (2000–2008).
expected weight, which is reasonably an eﬀect of a disturbed
intrauterine growth, resulting in small-for-gestational age
(SGA) or large-for-gestational age (LGA) infants. These are
often interesting outcomes but they can be studied more
directly.
3.6. Geographical and Seasonal Confounding. A confounding
situation can occur due to an uneven distribution of both
drug use and the occurrence or completeness of registration
of birth defects. Geographical confounding will be most
pronounced when the studied population is distributed over
a large area where variations in disease rates and/or in
therapeutic traditions may occur and where also occurrence
or registration of birth defects may vary. These two sources
of variation are usually independent, but if they covary,
a confounding can arise. Such an analysis is shown in
Figure 2 which compares rates of infants with relatively
severe malformations (varying between 2.25 and 3.76%) and
rates of women who reported the use of antiasthmatic drugs
in early pregnancy (varying between 2.20 and 4.89%) in
21 Swedish counties. A correlation analysis gives r = 0.13,
P = 0.57, which suggeststhat the twovariables do not covary
signiﬁcantly.
Sometimes there is a clear seasonality in drug use. A
typicalexampleisdrugsforallergywhichatleastinNorthern
Europe shows a peak of use during spring. A similar peak
is also seen in the use of antidepressants (Figure 3). If also
themalformationstudiedshowsaseasonality,aconfounding
may arise if the eﬀect of such drugs is studied. Obviously, it
is not the seasonality at birth which is of interest but the sea-
sonality at the formation of the malformation. An example is
a possible association between use of SSRI and hypospadias
[24] which could tentatively be due to the fact that use
of antidepressants in early pregnancy may coincide with
a peak of hypospadias in infants conceived during spring.
The seasonality of hypospadias is rather weak but there is a
peak among infants conceived during April and May which
correspondstothepeakinantidepressantuse(Figure 3).The
correlation between the monthly rate of antidepressant use12 Obstetrics and Gynecology International
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Figure 3: Rates of antidepressant use (percentage, unbroken line)
and of hypospadias (per thousand, broken line) for the diﬀerent
calendar months.
and the monthly rate of conceptions leading to hypospadias
is, however, rather weak and not statistically signiﬁcant (r =
0.26, P = 0.20), and this correlation is still weaker if the
formative period of hypospadias (8 weeks or more after
LMP) is considered instead.
3.7. Confounding by Indication. The strongest and most dif-
ﬁcult to control confounding is confounding by indication:
that the disease or complaint which is the reason for drug
use in itself aﬀects pregnancy outcome.
The use of insulin during early pregnancy is associated
with an increased risk for many types of congenital malfor-
mations. As insulin is practically only used at diabetes and a
pregnantwomanwithdiabetestype1alwaysgetsinsulin,itis
theoretically impossible to separate the eﬀect of disease and
treatment. As clinical experience indicates that strict blood
suger control in pregnant diabetic women is important for
the success of the pregnancy and also probably reduces the
birth defect risk, it is generally accepted that the increased
malformation risk is due to diabetes and not to insulin even
if it can be debated if strict scientiﬁc evidence for this exists.
In most instances, the degree of overlap between disease
and drug use is not so strong but to disentangle the
contribution of the drug and the underlying condition is
oftendiﬃcult.Wewilltakeanumberofexamplestoillustrate
the dilemma.
3.7.1. Epilepsy and Anticonvulsants. The ﬁrst study that
linked epilepsy with an increased risk for a birth defect
concerned orofacial clefts [28] and could not distinguish
between disease and treatment. Numerous studies have veri-
ﬁed that the relationship between epilepsy and birth defects
includes many diﬀerent malformations, for example, spina
biﬁda, cardiovascular defects, orofacial clefts, hypospadias,
that the eﬀects of diﬀerent anticonvulsants vary, and that
untreated epilepsy seems not to be associated with an
increased birth defect risk.
Anticonvulsants are also used for other medical con-
ditions than epilepsy, for example, as mode stabilizers at
bipolar disease and sometimes for neuropathic pain (e.g.,
gabapentin). No large enough studies have been published
to evaluate if such use carries a similar risk as when the drugs
are used at epilepsy.
The general opinion is that anticonvulsant drugs per se
represent a teratogenic risk, and notably for valproic acid
this risk can be large why such use should be avoided during
pregnancy.
3.7.2. Depression and Antidepressants. Antidepressants have
in general a low teratogenic potential but some data indicate
that tricyclic antidepressants (TCAs) carry a higher birth
defect risk than selective serotonin reuptake inhibitors
(SSRIs) do, while data for serotonin/noradrenalin inhibitors
(SNRIs) are still incomplete. The teratogenicity of TCA is
notably evident for cardiovascular defects—a similar eﬀect
is indicated in some studies for paroxetine but may be absent
for other SSRIs [29] while other studies have found also an
eﬀect of ﬂuoxetine [30].
More common eﬀects are seen after antidepressant use in
late pregnancy, resulting in preterm birth and increased risks
forvariousformsofneonatalmorbidity.Inthissituation,the
importance of the eﬀect of the underlying disease, usually
depression, has been much discussed. Some studies describe
such eﬀects associated with maternal depression but it is
not always clear if consideration has been taken to drug
treatments.
3.7.3. NVP and Antihistamines. A classical example of con-
founding by indication is the use of certain antihistamines
for the treatment of nausea and vomiting in pregnancy
(NVP). Studies of such antihistamines have shown a lower
than expected rate of birth defects in the oﬀspring and also
other signs of a better than expected pregnancy outcome
[26]. It does not seem likely that the drugs actually prevent
the occurrence of birth defects, and there is some evidence
thatthestrengthofNVPisafactorwhichpositivelycorrelates
with pregnancy outcome. The probable mechanism is that
among the factors causing NVP are hormones produced
from the placenta, so a strong NVP (perhaps needing
drug therapy) may indicate a well functioning placenta and
thereby a decreased risk for a congenital malformation or
other pregnancy complications.
3.7.4.HypertensionandAntihypertensives. Somestudieshave
associated the use of antihypertensive drugs in early preg-
nancy with an increased risk of birth defects and notably
cardiovascular defects. The ﬁrst major study found such
a link for ACE-inhibiting drugs [31] but a later study
[32] found no diﬀerence between such drugs and other
antihypertensives in the risk for birth defects. Little is known
about the eﬀect of untreated essential hypertonia on birth
defect risk but the possibility that the drug eﬀect is due to
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3.7.5. Infections and Antibiotics. Most antibiotics have no
apparent teratogenic eﬀects in man but in a few such asso-
ciations have been suggested, either from epidemiological
studies (e.g., erythromycin [33]) or from pharmacological
considerations (e.g., trimethoprim which has a folic-acid
antagonistic eﬀect [34]). Among infections, most interest
has been shown in viral infections because of the well-
known teratogenic eﬀect of rubella and some other viral
infections. Viral infections are no reason for antibiotic use
but undoubtedly such treatment is often given anyway. It is
also possible that adequate antibiotic treatment is given for a
secondary infection following a virus infection which could
have increased the birth defect risk. Secondary eﬀects of the
infection can also be considered, for example, the possible
harmful eﬀects of high fever [35].
3.7.6. How to Deal with the Problem of Confounding by
Indication? One straight forward way is to compare women
treated with drugs with women not treated with drugs but
with the same disease. A classical example is anticonvulsants
and epilepsy where untreated epilepsy repeatedly has been
shown to have no detrimental eﬀect on the embryo [36].
Epilepsyisaheterogeneousdiseasewithveryvariableseverity
anditisthereforelikelythatthediseasepanoramaisdiﬀerent
among untreated and treated women. Certain other diseases
are so severe that treatment is always needed, for example,
diabetes type 1, and untreated patients are nearly impossible
to ﬁnd.
A second possibility exists when various drugs can be
used at the same underlying disease. An example is the
use of SSRI drugs at maternal depression. Among the four
main SSRI drugs used in Sweden, a signiﬁcant diﬀerence
was seen between the eﬀect of paroxetine and the other
S S R Id r u g so nc a r d i o v a s c u l a rd e f e c t s( Table 8)[ 24]. This
approach,however,iscomplicatedbythefactthatSSRIdrugs
are used at many diﬀerent conditions other than depression.
One such indication is anxiety and panic disorders where a
special drug, for example, paroxetine, may be favoured. So
there may still remain a confounding by indication. Detailed
information on the indication for use may be diﬃcult to get
inastudylargeenoughforthedetectionofteratogeniceﬀects
on speciﬁc malformations. Also given the same underlying
disease, diﬀerences in severity could be related to drug selec-
tion.This,forinstance,couldexplainthediﬀerenceinterato-
genic eﬀects of tricyclic antidepressants and SSRI drugs [24].
Another example of the use of two alternative drugs
for similar (although not quite identical) reasons is ery-
thromycin and phenoxymethyl penicillin. The former drug
but not the latter was associated with an increased risk for a
cardiovascular defect [33].
In order to characterize disease status and severity,
various clinical measurements can be used. In small studies
this can be based on questionnaire or interview informa-
tion aimed at such a characterization, ideally performed
prospectively before the outcome of the pregnancy is known.
Examples are studies based on information from teratology
information services where, at the contact with the woman
who seeks advice, speciﬁc questions on the reason for the
Table 8: Association between maternal use of SSRI drug in early
pregnancy and occurrence of cardiovascular defects in the infant
[21]. Odds ratio (OR) with 95% conﬁdence intervals (95% CI)
adjusted for year of birth, maternal age, parity, smoking, and BMI.
The cardiovascular defect rates in the four SSRI groups diﬀer
signiﬁcantly: χ2
(3 d.f) = 12.5, P<0.01.
SSI drug
Number of
cardiovascular
defects
OR 95% CI
Fluoxetine 21 1.31 0.85–1.02
Citalopram 37 0.86 0.62–1.20
Paroxetine 24 1.66 1.09–2.53
Sertraline 26 0.74 0.50–1.09
drug use can be made and also some standardized quan-
tiﬁcation of disease severity. Unfortunately such projects
usually result in rather small numbers of exposed infants,
andforstudiesofbirthdefectrisks,theywouldmostlikelybe
stronglyunderpowered.Thesameistrueforspeciﬁcresearch
projects based on data from one or a few clinics dealing
with a speciﬁc group of diseases, for example, centres for the
treatment of epilepsy. In retrospective case-control studies, a
memory bias can be obtained not only on drug use, but also
on disease characterization.
Most studies on birth defect risks which are powered to
detect moderate risk increases must utilize register informa-
tionwherearecordingofdetaileddiseasehistoriesisdiﬃcult.
One way to solve the problem is to use a case-control design
and base disease evaluations on medical records, prepared
before the pregnancy outcome was known, if such records
can be retrieved and are reasonably well standardized.
Another possibility which has been used for instance
in studies by SSRI drugs [37] is to characterize disease
and disease severity by available health data, for example,
number of visits to doctors for speciﬁc reasons. Based on
such information a propensity score can be built for each
patient which makes it possible to match or adjust for
disease severity. The eﬃciency of this method depends on
the selection of variables used for the propensity scoring.
Often information from the time before the pregnancy is
used which may not be a valid scoring for the patient in the
beginning of the pregnancy when birth defects are formed.
3.8. How Eﬀective Is an Adjustment for Confounding? What-
ever the technique of identiﬁcation and adjustment for
confounding which has been used, the question of its
eﬀectiveness remains. The situation is rather simple if an
observed eﬀect disappears when a true confounder has been
taken into consideration, like in the examples of smoking or
drug use and the birth of an infant with Down syndrome
(see the previous). It is then reasonable to conclude that
no direct eﬀect of the exposure has been demonstrated. If
ar e s i d u a le ﬀect of the exposure remains, however, this can
be due to incomplete identiﬁcation or adjustment for the
confounder(s). Some examples will be discussed.
In most instances, the confounding eﬀect of maternal
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Table 9: The eﬀect of adjustment for some maternal characteristics on the eﬀect of tricyclic antidepressants (TCAs) on the occurrence of
infant cardiac defect and on the eﬀect of antidepressants on preterm birth.
Cardiac defects after TCA <37 weeks after antidepressants
Variables adjusted for OR 95% CI OR 95% CI
None (=crude) 1.64 1.14–2.36 1.60 1.50–1.72
Year of delivery 1.75 1.22–2.52 1.60 1.44–1.77
Year of delivery and maternal age 1.74 1.21–2.50 1.58 1.40–1.79
Year of delivery and maternal age and parity 1.74 1.21–2.50 1.54 1.37–1.77
Year of delivery and maternal age and smoking 1.72 1.19–2.49 1.44 1.23–1.69
Year of delivery and maternal age and smoking and BMI 1.68 1.15–2.45 1.42 1.32–1.52
Table 10: Eﬀect of stepwise adjustment for maternal characteristics in the analysis of the risk for drug-treated ADHD in infants conceived
by IVF [34].
Variables adjusted for OR 95% CI
None (=crude) 0.71 0.62–0.81
Year of delivery 0.77 0.68–0.87
Year of delivery, maternal age, parity, smoking and country of birth 0.91 0.81–1.05
Year of delivery, maternal age, parity, smoking, country of birth, and BMI 0.95 0.83–1.08
Year of delivery, maternal age, parity, smoking, country of birth, and education 1.14 0.99–1.31
Year of delivery, maternal age, parity, smoking, country of birth, and education,
with exclusion of non-cohabiting women
1.18 1.05–1.36
intervals will be adequate. When very strong eﬀects are seen
of maternal age, notably in the lower or upper end of the age
range, more exact maternal age adjustments, for example,
based on one-year intervals, may be needed. Examples are
the steeply increasing risk for a Down infant birth with high
maternal age and a steeply increasing risk for an infant with
gastroschisis with low maternal age. In both these examples,
the regression between age and outcome is nonlinear, that is
why a linear regression analysis may underestimate maternal
age as a risk factor.
If maternal smoking appears as a risk factor, adjustment
for any smoking may be insuﬃcient and so may a crude
division into <10 and ≥10 cigarettes per day. In the latter
group will be included both women who smoke 10 cigarettes
perdayandwomenwhosmoke20ormorecigarettesperday,
and the proportion of these groups may well vary between
women who have used for instance psychoactive drugs and
women who have not used such drugs. If the adjustment
for smoking results in a reduction of the risk estimate, one
should consider the possibility that the remaining estimate
may be too high due to crude information on smoking. A
similar eﬀe c tc a no c c u ra ta d j u s t m e n tf o rB M I ,i fo n l yc r u d e
groups are used.
An adjustment for the use of any other drug than the
drug under study may in a similar way be insuﬃcient if
the patterns of drug use diﬀer. A substantial percentage
of women using antidepressants also use sedatives while
adjustment for any other drug use will ineﬀectively adjust for
the possible eﬀect of the sedatives.
3.9. The Eﬀect of Adjusting for Confounding on Risk Estimates.
The eﬀects of confounders on outcome vary according to
the nature of exposure and outcome. The most important
eﬀects should be expected in analyses of drugs which are
used at diﬀerent rates in diﬀerent groups of women, for
instance, diﬀerent age groups. The confounding variables
must, however, also aﬀect outcome in order to be relevant.
Most variables studied in Table 2 had only moderate eﬀect
on the risk for any relatively severe malformation, that is why
the eﬀect of the clear diﬀerences in the use of antidepressants
in early pregnancy will be weak. In Table 9 it is also seen that
the stepwise adjustment for some of these variables does not
markedlychangetheriskestimateforacardiacmalformation
after maternal use of a tricyclic antidepressant in early
pregnancy: the estimates vary around 1.6 and 1.7, and the
crude estimate is close to the estimate after adjustment
for year of delivery, maternal age, parity, smoking in early
pregnancy, and prepregnancy BMI.
The table also shows similar stepwise adjustments for
risk estimates of preterm birth after maternal use of
antidepressants, and here the adjustment reduces the excess
risk with nearly one-third, from 60% increased risk to
42% increased risk, and the strongest eﬀects are seen from
maternal smoking and obesity.
In special circumtances, the signiﬁcance of confounding
becomes very important. One example is a recent study on
the risk for infants conceived after IVF to develop drug-
treated ADHD [38]. A summary is given in Table 10.T h e
crude OR indicates a statistically signiﬁcant protective eﬀect,
that IVF children have a lower risk for this condition than
other children. As in all studies of long-term eﬀect, year of
delivery can be an important confounder if exposure rate
(in this case use of IVF) increases during the observation
period while the follow-up time of the children decreases.
Adjustment for year of delivery increases the OR but it is
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characteristics including age, parity, smoking, country of
birth, and (in the next step) BMI removes the apparent
protective eﬀect and leaves an OR close to 1.0. As low
maternal education is associated with an increased risk
for infant ADHD, and high education with a decreased
risk, adjustment for maternal education increases the risk
estimates but it does not quite reach statistical signiﬁcance
(lower CI is 0.99). Also non-cohabitation in early pregnancy
is associated with an increased risk for ADHD and when
these (relatively few) women are removed from the analysis,
theORincreasesfurtherandbecomesstatisticallysigniﬁcant.
What we see here is the opposite eﬀects of some variables
on exposure (IVF) and outcome (drug-treated ADHD)
which initially results in an apparent protective eﬀect which
gradually disappears when such factors are added in the
analysis and ﬁnally results in an apparent over-risk. It should
be stressed that some of these factors (e.g., low maternal
education and not cohabiting) reasonably have no direct
eﬀects but may be proxies for two things: socioeconomic
level and possibly parental signs of ADHD with a genetic
background. So, for instance, some studies indicate that the
increased risk for ADHD if the mother smoked is due to the
fact that women with genes for ADHD and perhaps have
signs of ADHD smoke more than other women [39, 40].
The basic question if infants conceived by IVF do have an
increased risk for ADHD is not deﬁnitely solved. This may
be a good example of how complex and diﬃcult to handle
confounding can be under certain circumstances.
4. Concluding Remarks
The problem with confounding is not solved by uncritically
adding a number of variables to a logistic regression model.
Variables used for adjustment should be carefully selected
according to their properties to aﬀect both exposure rate
and outcome rate. It should be realized that eﬀorts to
adjust for them may be ineﬀective because the available
information on the confounders may be too crude or the
statistical models used may be inadequate. It should be
realized that the major problems in epidemiological studies
of the eﬀects of maternal drug use on birth defects are to be
found in biased data and low statistical power, not so much
in confounding. For studies of other pregnancy outcomes
like preterm birth, low birth weight, neonatal and long-
term morbidity, confounding plays a more important role.
The most diﬃcult confounding refers to confounding by
indication, often stated as important but usually without any
oﬀer of a good solution for its elimination.
Conﬂicts of Interests
The author declares no conﬂicts of interest.
Ethical Considerations
The analyses were performed within the responsibilities of
the National Board of Health and Welfare and therefore
no ethical approval from outside ethical committees was
needed.
Acknowledgment
ThestudiesreportedweresupportedbyagrantfromEvyand
Gunnar Sandberg Foundation, Lund, Sweden.
References
[ 1 ]B .A .J .K ¨ all´ en, “Methodological issues in the epidemiological
study of the teratogenicity of drugs,” Congenital Anomalies,
vol. 45, no. 2, pp. 44–51, 2005.
[2] B. K¨ all´ en, Drugs during Pregnancy, Nova Biomedical Books,
Nova Science Publishers, New York, NY, USA, 2009.
[3] J. Yerushalmy, “The relationship of parents’ cigarette smoking
to outcome of pregnancy-implications as to the problem of
inferring causation from observed associations,” American
Journal of Epidemiology, vol. 93, no. 6, pp. 443–456, 1971.
[4] A. Nikkil¨ a, B. K¨ all´ en, and K. Marˇ s´ al, “Fetal growth and
congenital malformations,” Ultrasound in Obstetrics and
Gynecology, vol. 29, no. 3, pp. 289–295, 2007.
[ 5 ]J .H a r r i s ,B .K a l l e n ,a n dE .R o b e r t ,“ D e s c r i p t i v ee p i d e m i o l o g y
of alimentary tract atresia,” Teratology, vol. 52, no. 1, pp. 15–
29, 1995.
[6] E. Robert, B. K¨ all´ en, and J. Harris, “The epidemiology of oro-
facial clefts. 1. Some general epidemiological characteristics,”
Journal of Craniofacial Genetics and Developmental Biology,
vol. 16, no. 4, pp. 234–241, 1996.
[7] K. K¨ all´ en, “Maternal smoking and congenital malformations,”
Fetal and Maternal Medicine Review, vol. 13, no. 1, pp. 63–86,
2002.
[8] K.K¨ all´ en,“Theimpactofmaternalsmokingduringpregnancy
on delivery outcome,” European Journal of Public Health, vol.
11, no. 3, pp. 329–333, 2001.
[9] B. K¨ allen, G. Lundberg, and A. ˚ Aberg, “Relationship between
vitaminuse,smoking,andnauseaandvomitingofpregnancy,”
Acta Obstetricia et Gynecologica Scandinavica, vol. 82, no. 10,
pp. 916–920, 2003.
[10] D. A. Dempsey and N. L. Benowitz, “Risks and beneﬁts of
nicotine to aid smoking cessation in pregnancy,” Drug Safety,
vol. 24, no. 4, pp. 277–322, 2001.
[11] S. K. Clarren and D. W. Smith, “The fetal alcohol syndrome,”
New England Journal of Medicine, vol. 298, no. 19, pp. 1063–
1067, 1978.
[12] K. Strandberg-Larsen, L. S. Skov-Ettrup, M. Grønbæk, A.-
M. N. Andersen, J. Olsen, and J. Tolstrup, “Maternal alcohol
drinking pattern during pregnancy and the risk for an
oﬀspring with an isolated congenital heart defect and in
particular a ventricular septal defect or an atrial septal defect,”
Birth Defects Research Part A, vol. 91, no. 7, pp. 616–622, 2011.
[13] S. Richardson, M. L. Browne, S. A. Rasmussen et al.,
“Associations between periconceptional alcohol consumption
and craniosynostosis, omphalocele, and gastroschisis,” Birth
Defects Research Part A, vol. 91, no. 7, pp. 623–630, 2011.
[14] C. P. Torfs, E. M. Velie, F. W. Oechsli, T. F. Bateson, and
C. J. R. Curry, “A population-based study of gastroschisis:
demographic, pregnancy, and lifestyle risk factors,” Teratology,
vol. 50, no. 1, pp. 44–53, 1994.
[15] M. I. Blomberg and B. K¨ all´ en, “Maternal obesity and morbid
obesity:theriskforbirthdefectsintheoﬀspring,”BirthDefects
Research Part A, vol. 88, no. 1, pp. 35–40, 2010.16 Obstetrics and Gynecology International
[16] A. ˚ Aberg, L. Westbom, and B. K¨ all´ en, “Congenital malforma-
tions among infants whose mothers had gestational diabetes
or preexisting diabetes,” Early Human Development, vol. 61,
no. 2, pp. 85–95, 2001.
[17] A. A. Rimm, A. C. Katayama, and K. P. Katayama, “A
meta-analysis of the impact of IVF and ICSI on major
malformations after adjusting for the eﬀect of subfertility,”
Journal of Assisted Reproduction and Genetics, vol. 28, no. 8,
pp. 699–705, 2011.
[18] B. K¨ all´ en, O. Finnstr¨ o m ,K .G .N y g r e n ,a n dP .O .O l a u s s o n ,
“In vitro fertilization (IVF) in Sweden: risk for congenital
malformations after diﬀerent IVF methods,” Birth Defects
Research Part A, vol. 73, no. 3, pp. 162–169, 2005.
[19] K. K¨ all´ en, “Maternal smoking and orofacial clefts,” Cleft
Palate-Craniofacial Journal, vol. 34, no. 1, pp. 11–16, 1997.
[20] E. J. Lammer, G. M. Shaw, D. M. Iovannisci, and R. H.
Finnell, “Maternal smoking, genetic variation of glutathione
S-transferases, and risk for orofacial clefts,” Epidemiology, vol.
16, no. 5, pp. 698–701, 2005.
[21] J. M. Elwood, J. Little, and H. Elwood, Epidemiology and
C o n t r o lo fN e u r a lT u b eD e f e c t s , vol. 20 of Monographs in
Epidemiology and Biostatistics, Oxford University Press, New
York, NY, USA, 1992.
[22] K K¨ all´ en, “F¨ orlossningsresultat bland invandrarkvinnor i
Sverige. (Delivery results among immigrant women in Swe-
den),” EpC Report 1998:1. National Board of Health and
Welfare.
[23] K. S. Au, A. Ashley-Koch, and H. Northrup, “Epidemiologic
and genetic aspects of spina biﬁda and other neural tube
defects,” Developmental Disabilities Research Reviews, vol. 16,
no. 1, pp. 6–15, 2010.
[24] M.ReisandB.K¨ all´ en,“Deliveryoutcomeaftermaternaluseof
antidepressant drugs in pregnancy: an update using Swedish
data,” Psychological Medicine, vol. 40, no. 10, pp. 1723–1733,
2010.
[ 2 5 ]T .F .O b e r l a n d e r ,W .W a r b u r t o n ,S .M i s r i ,W .R i g g s ,J .A g h a -
janian, and C. Hertzman, “Major congenital malformations
following prenatal exposure to serotonin reuptake inhibitors
and benzodiazepines using population-based health data,”
Birth Defects Research Part B, vol. 83, no. 1, pp. 68–76, 2008.
[26] B. K¨ all´ en and I. Mottet, “Delivery outcome after the use of
meclozine in early pregnancy,” European Journal of Epidemi-
ology, vol. 18, no. 7, pp. 665–669, 2003.
[27] B. K¨ all´ en, O. Finnstr¨ om, A. Lindam, E. Nilsson, K. G. Nygren,
and P. O. Olausson, “Selected neonatal outcomes in dizygotic
twins after IVF versus non-IVF pregnancies,” BJOG, vol. 117,
no. 6, pp. 676–682, 2010.
[28] S. R. Meadow, “Congenital abnormalities and anticonvulsant
drugs,” Proceedings of the Royal Society of Medicine, vol. 63, no.
1, pp. 48–49, 1970.
[29] B. A. J. K¨ all´ en and P. O. Olausson, “Maternal use of selective
serotonin re-uptake inhibitors in early pregnancy and infant
congenital malformations,” Birth Defects Research Part A, vol.
79, no. 4, pp. 301–308, 2007.
[30] H. Malm, M. Artama, M. Gissler, and A. Ritvanen, “Selective
serotonin reuptake inhibitors and risk for major congenital
anomalies,”ObstetricsandGynecology,vol.118,no.1,pp.111–
120, 2011.
[31] W.O.Cooper,S.Hernandez-Diaz,P.G.Arbogastetal.,“Major
congenital malformations after ﬁrst-trimester exposure to
ACE inhibitors,” New England Journal of Medicine, vol. 354,
no. 23, pp. 2443–2451, 2006.
[32] R. Lennest˚ al, P. Otterblad Olausson, and B. K¨ all´ en, “Maternal
use of antihypertensive drugs in early pregnancy and delivery
outcome, notably the presence of congenital heart defects in
the infants,” European Journal of Clinical Pharmacology, vol.
65, no. 6, pp. 615–625, 2009.
[33] B. A. J. K¨ all´ en, P. O. Olausson, and B. R. Danielsson, “Is
erythromycin therapy teratogenic in humans?” Reproductive
Toxicology, vol. 20, no. 2, pp. 209–214, 2005.
[34] I. Mylonas, “Antibiotic chemotherapy during pregnancy and
lactation period: aspects for consideration,” Archives of Gyne-
cology and Obstetrics, vol. 283, no. 1, pp. 7–18, 2011.
[35] S. S. Hashmi, M. S. Gallaway, D. K. Waller, P. H. Langlois, and
J. T. Hecht, “Maternal fever during early pregnancy and the
risk of oral clefts,” Birth Defects Research Part A,v o l .8 8 ,n o .3 ,
pp. 186–194, 2010.
[ 3 6 ]I .B o r t h e n ,M .G .E i d e ,A .K .D a l t v e i t ,a n dN .E .G i l h u s ,
“Obstetric outcome in women with epilepsy: a hospital-based,
retrospective study,” BJOG, vol. 118, no. 8, pp. 956–965, 2011.
[37] T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and
C. Hertzman, “Neonatal outcomes after prenatal exposure
to selective serotonin reuptake inhibitor antidepressants and
maternal depression using population-based linked health
data,” Archives of General Psychiatry, vol. 63, no. 8, pp. 898–
906, 2006.
[38] A.J.B.K¨ all´ en,O.O.Finnstr¨ om,A.P.Lindam,E.M.E.Nilsson,
K.-G. Nygren, and P. M. Otterblad Olausson, “Is there an
increased risk for drug treated attention deﬁcit/hyperactivity
disorderinchildrenbornafterinvitrofertilization?”European
Journal of Paediatric Neurology, vol. 15, no. 3, pp. 247–253,
2011.
[39] V. S. Knopik, “Maternal smoking during pregnancy and child
outcomes: real or spurious eﬀect?” Developmental Neuropsy-
chology, vol. 34, no. 1, pp. 1–36, 2009.
[40] A. Thapar, F. Rice, D. Hay et al., “Prenatal smoking might not
causeattention-deﬁcit/hyperactivitydisorder:evidencefroma
noveldesign,”BiologicalPsychiatry,vol.66,no.8,pp.722–727,
2009.